Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 1.00 |
| ▸ | MME | P08473 | 3/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omapatrilat SCHEMBL30924348 | 1.00 | ACE (1.00) | ACEMMEAPP | |
| Omapatrilat SCHEMBL4330098 | 1.00 | ACE (1.00) | ACEMMEAPP | |
| Omapatrilat SCHEMBL1047530 | 1.00 | ACE (1.00) | ACEMMEAPP | |
| Omapatrilat SCHEMBL130098 | 1.00 | ACE (1.00) | ACEMMEAPP | |
| Omapatrilat SCHEMBL30924347 | 1.00 | ACE (1.00) | ACEMMEAPP | |
| Omapatrilat SCHEMBL4818275 | 1.00 | ACE (1.00) | ACEMMEAPP | |
| Omapatrilat SCHEMBL23468397 | 1.00 | ACE (1.00) | ACEMMEAPP | |
| Omapatrilat SCHEMBL20130837 | 1.00 | ACE (1.00) | ACEMMEAPP | |
| SCHEMBL6891502 | 0.94 | ACE (0.89) | ACEMMEAPP | |
| SCHEMBL6894003 | 0.94 | ACE (0.89) | ACEMMEAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9041 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739293-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | AZURA OPHTHALMICS LTD (IL) | 2026-05-13 | — | — | EP | claimed |
| EP-4739291-A2 | ADMINISTRATION OF KERATOLYTICS TO OCULAR AND PERIOCULAR SURFACES | AZURA OPHTHALMICS LTD (IL) | 2026-05-13 | — | — | EP | claimed |
| WO-2026041906-A1 | SEMI-SOLID PHARMACEUTICAL COMPOSITION MICRO-DISPENSER | Azura Ophthalmics Ltd. (IL) | 2026-02-26 | — | — | WO | claimed |
| US-12521402-B2 | Biomarker and drug combinations for heart failure prediction | Endothelium Scanning Nanotechnology Limited (AU) | 2026-01-13 | — | — | US | claimed |
| US-20260000679-A9 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | ENDOTHELIUM SCANNING NANOTECHNOLOGY LTD (AU) | 2026-01-01 | — | — | US | claimed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| WO-2025012701-A2 | ADMINISTRATION OF KERATOLYTICS TO OCULAR AND PERIOCULAR SURFACES | Azura Ophthalmics Ltd. (IL) | 2025-01-16 | — | — | WO | claimed |
| WO-2025012700-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | Azura Ophthalmics Ltd. (IL) | 2025-01-16 | — | — | WO | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| WO-2024216053-A1 | SMALL MOLECULE CONTROL OF MEMBRANE AND SECRETED PROTEINS VIA HUMAN PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-10-17 | — | — | WO | claimed |
| EP-1106210-A2 | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications | Pfizer Products Inc. (US) | 2001-06-13 | — | — | EP | claimed |
| WO-2001040231-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-07 | — | — | WO | claimed |
| WO-2001027107-A2 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| EP-1087775-A1 | PREVENTING CEREBRAL INFARCTION THROUGH ADMINISTRATION OF ADP-RECEPTOR ANTIPLATELET AND ANTIHYPERTENSIVE DRUGS IN COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-04 | — | — | EP | claimed |
| WO-2001021602-A1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-03-29 | — | — | WO | claimed |
| WO-2001015674-A2 | USE OF INHIBITORS OF THE RENIN-ANGIOTENSIN SYSTEM IN THE PREVENTION OF CARDIOVASCULAR EVENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-03-08 | — | — | WO | claimed |
| US-6140319-A | ADMINISTERING AN VASOPEPTIDASE INHIBITOR FOR TREATING AND/OR RELIEVING THE SYMPTOMS OF ANGINA PECTORIS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-31 | — | — | US | claimed |
| WO-2000059506-A1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-12 | — | — | WO | claimed |
| WO-2000057883-A1 | USE OF VASOPEPTIDASE INHIBITORS TO TREAT ANGINA PECTORIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-10-05 | — | — | WO | claimed |
| WO-1999065500-A1 | PREVENTING CEREBRAL INFARCTION THROUGH ADMINISTRATION OF ADP-RECEPTOR ANTIPLATELET AND ANTIHYPERTENSIVE DRUGS IN COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-23 | — | — | WO | claimed |